Aptose Biosciences
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $712 | $712 |
Gross Profit | -117 | -108 | 599 | |
EBITDA | -6,869 | -7,337 | -9,651 | -12,349 |
EBIT | -6,965 | -7,439 | -9,759 | -12,462 |
Net Income | -6,953 | -7,252 | -9,596 | -12,285 |
Net Change In Cash | 0 | 0 | 712 | 712 |
Free Cash Flow | -10,376 | -5,778 | -11,709 | -9,503 |
Cash | 7,962 | 8,330 | 7,338 | 9,204 |
Basic Shares | 18,560 | 16,755 | 13,133 | 7,942 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -474 | -507 | -616 | -646 |
EBITDA | -52,268 | -39,658 | -64,162 | -57,509 |
EBIT | -52,356 | -40,165 | -64,778 | -58,156 |
Net Income | -51,207 | -41,053 | -65,261 | -54,708 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | -2,140 | -78,279 | 37,551 | |
Free Cash Flow | -44,619 | -32,346 | -43,516 | -33,970 |
Cash | 9,252 | 36,970 | 39,114 | 117,393 |
Basic Shares | 6,755 | 6,151 | 5,939 | 5,455 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.37 |
2024-06-30 | -$0.43 |
2024-03-31 | -$0.73 |
2023-12-31 | -$1.44 |
